Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up57.250 +1.450 (+2.599%)

21/09/2021 15:25

HUTCHMED (00013) starts phase III study

[ET Net News Agency, 21 September 2021] HUTCHMED (China) Limited (00013) announced that
it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of
surufatinib (SULANDA in China) in combination with toripalimab compared with FOLFIRI to
treat patients with advanced neuroendocrine carcinoma (NEC) who have progression of
disease or intolerable toxicity after previous first-line chemotherapy.
The study is a randomized, controlled, open-label, multi-centre study where
approximately 200 patients are expected to be enrolled. (RC)

Remark: Real time quote last updated: 26/11/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.